Novartis | NVS - Stock


Novartis reported $6.29B in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.13B 78M Jun/2026
Amgen USD 6.22B 34M Jun/2026
AstraZeneca USD 6.93B 362M Jun/2026
Bausch Health Companies USD 1.6B 1000K Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Canopy Growth CAD 110.51M 4.96M Mar/2026
Corcept Therapeutics USD 13.18M 295K Jun/2026
Drreddys Laboratories INR 76.53B 2.48B Mar/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
J&J USD 15.14B 561M Jun/2026
Merck USD 6.48B 179M Mar/2026
Novartis USD 6.22B 66M Jun/2026
Novartis USD 6.29B 135M Mar/2026
Pacira USD 134.57M 15.8M Jun/2026
Perrigo USD 1.06B 56.9M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
Phibro Animal Health USD 539.7M 22.35M Mar/2026
Prestige Brands USD 190.22M 31.08M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 24.12B 620M Jun/2026
Sanofi EUR 23.5B 812M Mar/2026
Supernus Pharmaceuticals USD 107.03M 3.74M Jun/2026
Zoetis USD 2.57B 24M Jun/2026